Meet the team

A team of healthcare and investment experts dedicated to creating lasting global health impact and supported by market-leading platform.

Investment team

A broad team of experts supported by a market leading platform

Alexandre Martin-Min
Managing Partner & Chair of Investment Committee
Cameron Irby
Associate, Healthcare Private Equity
Camila Alva Estabridis
Associate, Impact Investing
Clara Ezed (Odularu)
Director, Healthcare Private Equity
Dr Curt Labelle
Partner, Head of Healthcare Private Equity
Harry Waters
Director, Fund Management
Jalel Kallel
Principal, Private Equity Transactions
James Feeney
Associate, Fund Management
Jonathan Dean
Head of Fund Management
Niel Lategan
Due Diligence & Transaction
Romain Boulland
Shade Duffy
Principal, Impact Investing
Dr. Zina Affas Besse
Partner, Deputy Head of Healthcare Private Equity

Key Advisors

Support by leaders in Global Health, IP and health investing

Dr. Beat Mollet
IP specialist
Bill Greene, M.D.
Investor, Operator and Board Member
Daniel Bradbury
Investor, Entrepreneur, Operator and Board Member
Frederick St Goar, MD
Cardiology specialist
Marie-Christine Bissery, PhD.
Oncology specialist
Mads Dall, B.A., M.A.
Diabetes, business development/commercial specialist and investor
Professor (Hon.) Mark Sullivan, AO BSc
Global health specialist
Dr. Niti Pall
Global health specialist
Renuka Gadde, BSC., MBA
Global Health and MedTech specialist
Rob Binney, B.A.
Medical device commercial specialist
Shacey Petrovic, Bsc
Diabetes and women's health business specialist
Susan MacDonald, MD
Clinical Ophthalmology specialist

Risk Warning

No assurance can be given that our strategies will be successful. Investors can lose some or all of their capital invested.


    Companies or assets are shown for illustrative purposes only and should not be considered as advice or a recommendation for an investment strategy.

    This marketing communication does not constitute on the part of AXA Investment Managers a solicitation or investment, legal or tax advice. This material does not contain sufficient information to support an investment decision.
    Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

    ESG disclaimer

    The ESG data used in the investment process are based on ESG methodologies which rely in part on third party data, and in some cases are internally developed. They are subjective and may change over time. Despite several initiatives, the lack of harmonised definitions can make ESG criteria heterogeneous. As such, the different investment strategies that use ESG criteria and ESG reporting are difficult to compare with each other. Strategies that incorporate ESG criteria and those that incorporate sustainable development criteria may use ESG data that appear similar but which should be distinguished because their calculation method may be different.